Results 21 to 30 of about 19,908 (254)

Super-refractory status epilepticus and pharmacoresistant epilepsy in an infant with hemorrhagic shock and encephalopathy syndrome [PDF]

open access: yesSrpski Arhiv za Celokupno Lekarstvo, 2021
Introduction. Hemorrhagic shock and encephalopathy syndrome (HSES) is a rare disorder with prevalence at an early age. The main features of HSES are acute diarrhea, shock, disseminated intravascular coagulation, multisystem impairment, and encephalopathy.
Kravljanac Ružica   +3 more
doaj   +1 more source

P2X receptors as targets for the treatment of status epilepticus. [PDF]

open access: yes, 2013
Prolonged seizures are amongst the most common neurological emergencies. Status epilepticus is a state of continuous seizures that is life-threatening and prompt termination of status epilepticus is critical to protect the brain from permanent damage ...
Diaz-Hernandez, Miguel   +3 more
core   +1 more source

Stiripentol in refractory status epilepticus [PDF]

open access: yesEpilepsia, 2013
SummaryBenzodiazepines (BZDs), which enhance γ‐aminobutyric acid (GABAA) receptor–mediated inhibition, are the first‐line therapy for treatment of status epilepticus (SE). However, pharmacoresistance toBZDs develops rapidly afterSEinitiation. This is due to an activity‐dependent internalization ofBZD‐sensitiveGABAAreceptors duringSE.
Denise K, Grosenbaugh, David D, Mott
openaire   +2 more sources

Ketamine use in refractory status epilepticus associated with anti-NMDA receptor antibody encephalitis

open access: yesEpilepsy & Behavior Reports, 2019
Purpose: Anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDAr encephalitis) is an auto-immune disorder associated with the production of antibodies against NR1 and NR2 sub units of the NMDA receptor.
Jonathan D. Santoro, MD   +2 more
doaj   +1 more source

Status epilepticus: impact of therapeutic coma on outcome. [PDF]

open access: yes, 2015
OBJECTIVES: Therapeutic coma is advocated in guidelines for management of refractory status epilepticus; this is, however, based on weak evidence. We here address the specific impact of therapeutic coma on status epilepticus outcome.
Burnand, B.   +5 more
core   +1 more source

Super-Refractory Status Epilepticus Treated with High Dose Perampanel: Case Series and Review of the Literature

open access: yesCase Reports in Critical Care, 2019
Introduction. Acute symptomatic seizures are frequent in the critically ill patient and can be difficult to treat. The novel anticonvulsant perampanel may be effective in the treatment of status epilepticus considering its mechanism of action of being an
Christopher R. Newey   +4 more
doaj   +1 more source

Neuroinflammatory targets and treatments for epilepsy validated in experimental models [PDF]

open access: yes, 2017
A large body of evidence that has accumulated over the past decade strongly supports the role of inflammation in the pathophysiology of human epilepsy.
Aronica, Eleonora   +17 more
core   +5 more sources

Deep brain stimulation of the centromedian thalamic nucleus for the treatment of FIRES

open access: yesEpilepsia Open, 2022
Febrile infection‐related epilepsy syndrome (FIRES) is a rare, life‐threatening complication of febrile illness in previously healthy individuals followed by super‐refractory status epilepticus.
Jasmine L. Hect   +3 more
doaj   +1 more source

Refractory and super-refractory status epilepticus and evidence for the use of ketamine: a scope review [PDF]

open access: yesJournal of Neurocritical Care, 2023
Status epilepticus (SE) is a neurological emergency with serious consequences for neuronal tissues, therefore, it is considered the most serious manifestation of epilepsy.
Luis Espinosa   +3 more
doaj   +1 more source

New-Onset Refractory Status Epilepticus with Claustrum Damage: Definition of the Clinical and Neuroimaging Features [PDF]

open access: yes, 2017
New-onset refractory status epilepticus (NORSE) is a rare but challenging condition occurring in a previously healthy patient, often with no identifiable cause.
Alexopoulos, Haris   +11 more
core   +1 more source

Home - About - Disclaimer - Privacy